Other Events ·
Korro Bio doses first cohort in Phase 1/2 trial of KRRO-121 for hyperammonemia
KRROKorro Bio, Inc.
Korro Bio announced the dosing of the first cohort of healthy volunteers in its ANCHOR Phase 1/2 clinical trial for KRRO-121, a GalNAc-conjugated RNA-editing oligonucleotide. The single ascending dose study is enrolling up to 30 participants across five cohorts to evaluate safety and pharmacokinetics. Dosing of patients with urea cycle disorders is expected to begin in the first half of 2027, with interim results anticipated in the second half of that year. Korro Bio operates as a clinical-stage biopharmaceutical company developing genetic medicines using its proprietary RNA editing platform.